{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:51Z","timestamp":1792716951888,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,8]],"date-time":"2027-06-08T00:00:00Z","timestamp":1812412800000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA226906-01A"],"award-info":[{"award-number":["R01 CA226906-01A"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CCSG P30CA016058"],"award-info":[{"award-number":["CCSG P30CA016058"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jpet.2026.104946","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:57:33Z","timestamp":1779299853000},"page":"104946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circumvention of acquired resistance to topoisomerase II-targeted anticancer agents in HL-60 leukemia cells by prevention of intronic polyadenylation"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8419-0698","authenticated-orcid":false,"given":"Xinyu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1222-0739","authenticated-orcid":false,"given":"Sydney R.","family":"Cassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8331-9642","authenticated-orcid":false,"given":"Sarah E.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0381-9356","authenticated-orcid":false,"given":"Junan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-8741","authenticated-orcid":false,"given":"Terry S.","family":"Elton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5414-573X","authenticated-orcid":false,"given":"Jack C.","family":"Yalowich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.jpet.2026.104946_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jmb.2012.07.014","article-title":"The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage","volume":"424","author":"Wendorff","year":"2012","journal-title":"J Mol Biol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104946_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104946_bib3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/nar\/gkn937","article-title":"The DNA cleavage reaction of topoisomerase II: wolf in sheep\u2019s clothing","volume":"37","author":"Deweese","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.104946_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/1759-7714.13289","article-title":"Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin","volume":"11","author":"Sakurai","year":"2020","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.jpet.2026.104946_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","article-title":"New mechanistic and functional insights into DNA topoisomerases","volume":"82","author":"Chen","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrd3404","article-title":"Interfacial inhibitors: targeting macromolecular complexes","volume":"11","author":"Pommier","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"10.1016\/j.jpet.2026.104946_bib8","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14656566.2019.1621292","article-title":"Topoisomerase II inhibitors in AML: past, present, and future","volume":"20","author":"Economides","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jpet.2026.104946_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.semcdb.2019.05.006","article-title":"Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines","volume":"98","author":"Capel\u00f4a","year":"2020","journal-title":"Semin Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.jpet.2026.104946_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/sym14071309","article-title":"Structural and biochemical basis of etoposide-resistant mutations in topoisomerase II\u03b1","volume":"14","author":"Gibson","year":"2022","journal-title":"Symmetry"},{"key":"10.1016\/j.jpet.2026.104946_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fphar.2013.00089","article-title":"Mechanisms regulating resistance to inhibitors of topoisomerase II","volume":"4","author":"Ganapathi","year":"2013","journal-title":"Front Pharmacol"},{"issue":"16","key":"10.1016\/j.jpet.2026.104946_bib13","first-page":"4542","article-title":"Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression","volume":"49","author":"Harker","year":"1989","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.jpet.2026.104946_bib14","first-page":"1707","article-title":"Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line","volume":"55","author":"Harker","year":"1995","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jpet.2026.104946_bib15","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1349-7006.2005.00111.x","article-title":"Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha","volume":"96","author":"de","year":"2005","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.jpet.2026.104946_bib16","first-page":"756","article-title":"Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line","volume":"54","author":"Feldhoff","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.104946_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.818668","article-title":"The role of alternative polyadenylation in the regulation of subcellular RNA localization","volume":"12","author":"Arora","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrm.2016.116","article-title":"Alternative polyadenylation of mRNA precursors","volume":"18","author":"Tian","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13046-021-01852-7","article-title":"Alternative polyadenylation: methods, mechanism, function, and role in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.104946_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41576-025-00928-w","article-title":"Regulation of gene expression by alternative polyadenylation in health and disease","volume":"27","author":"Tian","year":"2026","journal-title":"Nat Rev Genet"},{"issue":"13","key":"10.1016\/j.jpet.2026.104946_bib21","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.3390\/cancers14133148","article-title":"Intronic polyadenylation in acquired cancer drug resistance circumvented by utilizing CRISPR\/Cas9 with homology-directed repair: the tale of human DNA topoisomerase II\u03b1","volume":"14","author":"Elton","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1101\/gr.5532707","article-title":"Widespread mRNA polyadenylation events in introns indicate dynamic interplay between polyadenylation and splicing","volume":"17","author":"Tian","year":"2007","journal-title":"Genome Res"},{"issue":"7","key":"10.1016\/j.jpet.2026.104946_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade4814","article-title":"Alternative polyadenylation alters protein dosage by switching between intronic and 3\u2032UTR sites","volume":"9","author":"de Prisco","year":"2023","journal-title":"Sci Adv"},{"issue":"7721","key":"10.1016\/j.jpet.2026.104946_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-018-0465-8","article-title":"Widespread intronic polyadenylation inactivates tumour suppressor genes in leukaemia","volume":"561","author":"Lee","year":"2018","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.jpet.2026.104946_bib25","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1096\/fj.07-8809com","article-title":"Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta","volume":"21","author":"Thomas","year":"2007","journal-title":"FASEB J"},{"issue":"42","key":"10.1016\/j.jpet.2026.104946_bib26","doi-asserted-by":"crossref","first-page":"32233","DOI":"10.1074\/jbc.M109.095695","article-title":"Alternative splicing and polyadenylation contribute to the generation of hERG1 C-terminal isoforms","volume":"285","author":"Gong","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/ijms22020863","article-title":"Regulation of Kv11.1 isoform expression by polyadenylate binding protein nuclear 1","volume":"22","author":"Stump","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2026.104946_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev-genet-120116-024704","article-title":"Regulation by 3\u2032-untranslated regions","volume":"51","author":"Mayr","year":"2017","journal-title":"Annu Rev Genet"},{"issue":"11","key":"10.1016\/j.jpet.2026.104946_bib29","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/emboj\/cdg259","article-title":"Recognition of GU-rich polyadenylation regulatory elements by human CstF-64 protein","volume":"22","author":"P\u00e9rez Ca\u00f1adillas","year":"2003","journal-title":"EMBO J"},{"issue":"10","key":"10.1016\/j.jpet.2026.104946_bib30","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1016\/j.celrep.2019.02.049","article-title":"Regulation of intronic polyadenylation by PCF11 impacts mRNA expression of long genes","volume":"26","author":"Wang","year":"2019","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005768","article-title":"Prp4 kinase grants the license to splice: control of weak splice sites during spliceosome activation","volume":"12","author":"Eckert","year":"2016","journal-title":"PLoS Genet"},{"issue":"8","key":"10.1016\/j.jpet.2026.104946_bib32","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/MCB.01071-09","article-title":"Competing upstream 5\u2032 splice sites enhance the rate of proximal splicing","volume":"30","author":"Hicks","year":"2010","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1128\/MCB.06423-11","article-title":"RBFOX2 promotes protein 4.1R exon 16 selection via U1 snRNP recruitment","volume":"32","author":"Huang","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.jpet.2026.104946_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/molpharm.120.000173","article-title":"CRISPR\/Cas9 genome editing of the human topoisomerase II\u03b1 intron 19 5\u2032 splice site circumvents etoposide resistance in human leukemia K562 cells","volume":"99","author":"Hernandez","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2026.104946_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx1227","article-title":"CRISPR\/Cas9-mediated modulation of splicing efficiency reveals short splicing isoform of Xist RNA is sufficient to induce X-chromosome inactivation","volume":"46","author":"Yue","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2026.104946_bib36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/1066527041410418","article-title":"Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals","volume":"11","author":"Yeo","year":"2004","journal-title":"J Comput Biol"},{"issue":"21","key":"10.1016\/j.jpet.2026.104946_bib37","first-page":"4962","article-title":"Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone","volume":"55","author":"Harker","year":"1995","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jpet.2026.104946_bib38","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/molpharm.124.000868","article-title":"Circumvention of topoisomerase II\u03b1 intron 19 intronic polyadenylation in acquired etoposide-resistant human leukemia K562 cells","volume":"106","author":"Wang","year":"2024","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1124\/jpet.116.237107","article-title":"Alternative RNA processing of topoisomerase II\u03b1 in etoposide-resistant human leukemia K562 cells: intron retention results in a novel C-terminal truncated 90-kDa isoform","volume":"360","author":"Kanagasabai","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.104946_bib41","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/bjc.1994.131","article-title":"Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells","volume":"69","author":"Ritke","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jpet.2026.104946_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.redox.2013.12.020","article-title":"OpenComet: an automated tool for comet assay image analysis","volume":"2","author":"Gyori","year":"2014","journal-title":"Redox Biol"},{"key":"10.1016\/j.jpet.2026.104946_bib43","series-title":"In Situ Detection of DNA Damage: Methods and Protocols","first-page":"179","article-title":"The comet assay","author":"Olive","year":"2002"},{"issue":"41","key":"10.1016\/j.jpet.2026.104946_bib44","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1021\/bi00105a020","article-title":"Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform","volume":"30","author":"Harker","year":"1991","journal-title":"Biochemistry"},{"issue":"23","key":"10.1016\/j.jpet.2026.104946_bib45","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1073\/pnas.85.23.8998","article-title":"Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer","volume":"85","author":"Frohman","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-1119(98)00468-5","article-title":"Structural organization of the human TOP2A and TOP2B genes","volume":"221","author":"Lang","year":"1998","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13059-015-0749-3","article-title":"Regulation of constitutive and alternative mRNA splicing across the human transcriptome by PRPF8 is determined by 5\u2032 splice site strength","volume":"16","author":"Wickramasinghe","year":"2015","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98965-y","article-title":"Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair","volume":"11","author":"Schubert","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.jpet.2026.104946_bib49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jpet.2026.104946_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jbiotec.2016.11.011","article-title":"Enhanced CRISPR\/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA","volume":"241","author":"Liang","year":"2017","journal-title":"J Biotechnol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1124\/jpet.123.002038","article-title":"Use of CRISPR\/Cas9 with homology-directed repair to gene-edit topoisomerase II \u03b2 in human leukemia K562 cells: generation of a resistance phenotype","volume":"389","author":"Carvajal-Moreno","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2026.104946_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.pa.34.040194.001203","article-title":"DNA topoisomerases: essential enzymes and lethal targets","volume":"34","author":"Chen","year":"1994","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"24","key":"10.1016\/j.jpet.2026.104946_bib53","first-page":"6592","article-title":"Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines","volume":"51","author":"Fry","year":"1991","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.104946_bib54","first-page":"65","article-title":"Accumulation of true single strand breaks and AP sites in base excision repair deficient cells","volume":"694","author":"Luke","year":"2010","journal-title":"Mutat Res"},{"issue":"2","key":"10.1016\/j.jpet.2026.104946_bib55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1006\/excr.1999.4446","article-title":"The cytochrome b5 tail anchors and stabilizes subdomains of human DNA topoisomerase II alpha in the cytoplasm of retrovirally infected mammalian cells","volume":"249","author":"Soltermann","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jpet.2026.104946_bib56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/bjc.1996.231","article-title":"Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide","volume":"73","author":"Vassetzky","year":"1996","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1097-0215(20001001)88:1<99::AID-IJC16>3.0.CO;2-4","article-title":"Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells","volume":"88","author":"Ernst","year":"2000","journal-title":"Int J Cancer"},{"issue":"10 Pt A","key":"10.1016\/j.jpet.2026.104946_bib58","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jmb.2015.10.023","article-title":"Structural biology and regulation of protein import into the nucleus","volume":"428","author":"Christie","year":"2016","journal-title":"J Mol Biol"},{"issue":"16","key":"10.1016\/j.jpet.2026.104946_bib59","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1073\/pnas.93.16.8288","article-title":"Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms","volume":"93","author":"Biersack","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"47","key":"10.1016\/j.jpet.2026.104946_bib60","doi-asserted-by":"crossref","first-page":"16645","DOI":"10.1021\/bi981391l","article-title":"Characterization of DNA topoisomerase II alpha\/beta heterodimers in HeLa cells","volume":"37","author":"Gromova","year":"1998","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.jpet.2026.104946_bib61","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1124\/mol.117.111567","article-title":"The novel C-terminal truncated 90-kDa isoform of topoisomerase II \u03b1 (TOP2 \u03b1\/90) is a determinant of etoposide resistance in K562 leukemia cells via heterodimerization with the TOP2 \u03b1\/170 isoform","volume":"93","author":"Kanagasabai","year":"2018","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104946_bib62","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jpet.2026.104946_bib63","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33244-x","article-title":"High fidelity CRISPR\/Cas9 increases precise monoallelic and biallelic editing events in primordial germ cells","volume":"8","author":"Idoko-Akoh","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2026.104946_bib65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12703\/r\/9-20","article-title":"CRISPR-based strategies for targeted transgene knock-in and gene correction","volume":"9","author":"Lau","year":"2020","journal-title":"Fac Rev"},{"issue":"1","key":"10.1016\/j.jpet.2026.104946_bib66","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/s41598-023-28732-8","article-title":"Rapid clonal identification of biallelic CRISPR\/Cas9 knock-ins using SNEAK PEEC","volume":"13","author":"Singh","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jpet.2026.104946_bib67","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.3390\/ijms19092765","article-title":"TOP2B: the first thirty years","volume":"19","author":"Austin","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:21:33Z","timestamp":1785399693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0022356526011456"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104946","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circumvention of acquired resistance to topoisomerase II-targeted anticancer agents in HL-60 leukemia cells by prevention of intronic polyadenylation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104946"}}